×
Illumina Inventory 2010-2025 | ILMN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Illumina inventory for the quarter ending March 31, 2025 was
$537M
, a
8.05% decline
year-over-year.
Illumina inventory for 2024 was
$0.547B
, a
6.81% decline
from 2023.
Illumina inventory for 2023 was
$0.587B
, a
3.35% increase
from 2022.
Illumina inventory for 2022 was
$0.568B
, a
31.79% increase
from 2021.
View More
Illumina Inventory 2010-2025 | ILMN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Illumina inventory for 2024 was
$0.547B
, a
6.81% decline
from 2023.
Illumina inventory for 2023 was
$0.587B
, a
3.35% increase
from 2022.
Illumina inventory for 2022 was
$0.568B
, a
31.79% increase
from 2021.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$209.6B
Amgen (AMGN)
$149.1B
Gilead Sciences (GILD)
$130.2B
Vertex Pharmaceuticals (VRTX)
$125.6B
Bristol Myers Squibb (BMY)
$100.2B
CSL (CSLLY)
$74.3B
GSK (GSK)
$74.1B
Regeneron Pharmaceuticals (REGN)
$61.6B
Argenex SE (ARGX)
$36.2B
Alnylam Pharmaceuticals (ALNY)
$30.5B
BioNTech SE (BNTX)
$23.7B
BeiGene (ONC)
$22.8B
Biogen (BIIB)
$17.4B
Genmab (GMAB)
$13.3B
Genmab (GNMSF)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$11.3B
Incyte (INCY)
$11.3B
Ascendis Pharma (ASND)
$10.1B
Exelixis (EXEL)
$10B
Swedish Orphan Biovitrum (BIOVF)
$9.6B
Moderna (MRNA)
$9.6B
QIAGEN (QGEN)
$9B
Exact Sciences (EXAS)
$7.7B
Bio-Techne Corp (TECH)
$7.6B
Repligen (RGEN)
$7.3B
Halozyme Therapeutics (HALO)
$7.3B
Roivant Sciences (ROIV)
$7.2B
Revolution Medicines (RVMD)
$6.8B
Bio-Rad Laboratories (BIO.B)
$6.3B